Investor News

Acorda Therapeutics Completes $11.5 Million Private Financing


Hawthorne, NY March 4, 2004 - Acorda Therapeutics announced today that it has raised $11.5 million in a private financing comprising new and existing institutional investors.

Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury (SCI), multiple sclerosis (MS) and related central nervous system disorders. The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 trials for MS. Acorda's technology platform also includes valrocemide, which is in clinical development for the treatment of epilepsy and bipolar disorder. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain.

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At COMPANY NAME, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to COMPANY NAME to send you the requested Investor Email Alert updates.

* Required